Business Wire

CA-BRIMSTONE-ENERGY

Share
Brimstone Energy Announces Financing to Accelerate Development of the First-Ever Zero-Carbon Portland Cement

Brimstone Energy has secured financing co-led by DCVC and Breakthrough Energy Ventures (BEV) to develop zero-carbon Portland cement. In addition to the $5.1 million financing, the company has also received $2 million in grants from ARPA-E, the National Science Foundation, and others.

Cement is used all over the world as the basic ingredient in concrete, mortar, and other building materials, and has two key components, Portland cement and supplementary cementitious material (SCM). Today, Portland cement is made by heating limestone and clay or other materials in kilns, a process responsible for about 8% of global CO2 emissions (5.5% of global greenhouse gas emissions)—about the same as cars. SCM is produced as a byproduct of burning coal in powerplants and steel mills, and is becoming more expensive as global energy production relies less on coal.

Cody Finke, co-founder & CEO of Brimstone, commented, "The cement industry is currently reliant on coal-fired power plants and blast-furnaces. This dependency worked in the coal-dominated past, but the world is rapidly transitioning away from coal. In our modern energy system, the process that Brimstone is developing is more economically appropriate and sustainable.”

For the world to reach net-zero CO2 emissions, and also meet the building demands of the future, cement production must be decarbonized. Brimstone’s technology produces ordinary Portland cement, identical in every way to conventionally manufactured cement, but without releasing CO2 . Brimstone’s new process also produces SCM, identical in every way to conventional SCM, without burning coal. At scale, Brimstone’s breakthrough will make cement at or below market prices, solving both the problems of emissions and scarcity of raw materials, without increasing cost or risk for customers.

Kelly Chen, Partner at DCVC, added, “This isn’t carbon capture, or a cement alternative. Brimstone’s technology doesn’t change the chemistry of Portland cement. It’s a clean process with no CO2 byproduct that also produces SCM without burning coal. Our investment in Brimstone exemplifies DCVC’s work of over a decade backing brilliant entrepreneurs solving trillion-dollar problems at the forefront of climate resiliency.”

“Cement production is a major contributor to global carbon emissions, and we are focused on fixing that by investing in innovative companies like Brimstone,” said Carmichael Roberts of Breakthrough Energy Ventures. “Brimstone has the vision to reduce the cost, complexity, and emissions associated with this critical material.”

The new funding will support product development and hiring. Brimstone’s products will solve two key problems for cement producers:

  1. Reducing liability: CO2 emissions are increasingly a liability for cement companies as more governments pass laws like California's SB 596, mandating that the cement industry cut emissions by 100% by the year 2045.
  2. Fixing supply-chain issues and reducing costs : Brimstone’s co-production of Portland cement and SCM will end the complex and expensive logistics headache associated with sourcing supplementary cementitious materials from the coal industry.

Hugo Leandri, co-founder and CTO of Brimstone, remarked, “Major industrial processes only change every hundred years or so, and they always change towards market simplification. With over a century since a major innovation in cement, it’s time for a change.”

Brimstone is engaging with cement companies, architects, structural engineering firms, and concrete companies through their First Builders initiative, which is seeking to build a coalition of industry players and early adopters, who will get early access as Brimstone begins to scale. If you are an interested company or firm, email firstbuilders@brimstone.energy to participate.

About Brimstone Energy

Brimstone Energy uses proprietary technology to produce carbon-neutral Portland cement and supplementary cementitious materials. While at Caltech, Co-founders Cody Finke and Hugo Leandri conceived of the vision to decarbonize cement production by inventing better technology to work within the existing cement industry. Brimstone is backed by top investors—including DCVC, Breakthrough Energy Ventures, and the Collaborative Fund. To learn more, follow Brimstone on Twitter and LinkedIn at @BrimstoneEnergy , visit the website: www.brimstone.energy , or reach out directly: info@brimstone.energy .

About DCVC

DCVC backs entrepreneurs solving trillion-dollar problems to multiply the benefits of capitalism for everyone while reducing its costs. For over twenty years, DCVC and its principals have backed brilliant entrepreneurs applying Deep Tech, from the earliest stage and beyond, to pragmatically and cost-effectively tackle previously unsolvable problems in nearly every industry, especially those that haven’t seen material technological progress in decades. Together, we have created tens of billions of dollars of value while also making the world a markedly better place. Visit dcvc.com to learn more.

About Breakthrough Energy Ventures

Backed by many of the world’s top business leaders, Breakthrough Energy Ventures (BEV) invests in cutting-edge companies that will lead the world to net-zero emissions. BEV has more than $2 billion in committed capital to support bold entrepreneurs building companies that can significantly reduce emissions from agriculture, buildings, electricity, manufacturing, and transportation. BEV’s strategy links government-funded research and patient, risk-tolerant capital to bring transformative clean energy innovations to market as quickly as possible.

The first fund was created in 2016 as part of the Breakthrough Energy network of initiatives and entities, which include investment funds, non-profit and philanthropic programs, and policy efforts linked by a shared commitment to scale the technologies needed to address climate change and achieve a path to net zero emissions by 2050. Visit www.breakthroughenergy.org to learn more.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye